ANIK Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
32.6M
+10.1%
29.6M
-3.3%
30.6M
+10.1%
27.8M
-1.4%
28.2M
Cost of Revenue
11.4M
+7.1%
10.6M
-7.2%
11.4M
-6.5%
12.2M
-11.7%
13.9M
Gross Profit
21.2M
+11.8%
19.0M
-0.9%
19.2M
+23.1%
15.6M
+8.5%
14.4M
Operating Expenses
18.3M
-25.3%
24.5M
+32.1%
18.5M
-1.5%
18.8M
+1.5%
18.5M
R&D
7.3M
+9.4%
6.7M
+4.0%
6.5M
-7.1%
6.9M
+10.0%
6.3M
SG&A
10.9M
-38.4%
17.8M
+47.1%
12.1M
+1.8%
11.9M
-2.9%
12.2M
Operating Income
3.0M
+153.8%
-5488000
-949.5%
646.0K
+120.0%
-3233000
+22.7%
-4180000
EBITDA
4.5M
+209.3%
-4081000
-307.8%
2.0M
+207.3%
-1830000
+33.8%
-2764000
Net Income
3.3M
+165.4%
-5056000
-1831.5%
292.0K
+112.5%
-2329000
+41.3%
-3970000
EPS (Basic)
$0.25
+167.6%
$-0.37
-1950.0%
$0.02
+112.5%
$-0.16
+42.9%
$-0.28
EPS (Diluted)
$0.24
+164.9%
$-0.37
-1950.0%
$0.02
+112.5%
$-0.16
+42.9%
$-0.28
Shares (Diluted)
13.7M
+1.4%
13.5M
-4.2%
14.1M
-2.1%
14.4M
-0.7%
14.5M
Anika Therapeutics (ANIK) โ€” Financials